دورية أكاديمية
A Real-life Study of Brexpiprazole as an Adjunctive Treatment for Major Depressive Disorder in Asian Patients in Singapore (BADA).
| العنوان: | A Real-life Study of Brexpiprazole as an Adjunctive Treatment for Major Depressive Disorder in Asian Patients in Singapore (BADA). |
|---|---|
| المؤلفون: | Mok YM; Department of Mood and Anxiety, Institute of Mental Health, Singapore., Tan PLL; Department of Psychiatry, Tan Tock Seng Hospital, Singapore., Bose R; Medical Affairs, Lundbeck Singapore Pte Ltd, Singapore., Herr KJ; Medical Affairs, Lundbeck Singapore Pte Ltd, Singapore., Ung KEK; Adam Road Medical Centre, Singapore. |
| المصدر: | Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology [Clin Psychopharmacol Neurosci] 2024 Aug 31; Vol. 22 (3), pp. 531-536. Date of Electronic Publication: 2024 Mar 12. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Korean College of Neuropsychopharmacology Country of Publication: Korea (South) NLM ID: 101207332 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1738-1088 (Print) Linking ISSN: 17381088 NLM ISO Abbreviation: Clin Psychopharmacol Neurosci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Seoul : Korean College of Neuropsychopharmacology, c2003- |
| مستخلص: | Objective: : To investigate the effectiveness and safety of brexpiprazole as an adjunctive treatment to antidepressant therapy (ADT) in Asian adults with major depressive disorder (MDD) and inadequate response in a real-life clinical setting in Singapore. Methods: : This was a prospective, observational 3-month study of patients with MDD who had brexpiprazole added to their existing ADT. The study was conducted at two sites in Singapore between September 2020 and October 2021. The co-primary endpoints were Patient Health Questionnaire-9 (PHQ-9) and Clinical Global Impression-Severity (CGI-S). Other endpoints included Clinical Global Impression-Improvement (CGI-I), Sheehan Disability Scale (SDS), Generalized Anxiety Disorder 7-item scale (GAD-7), and safety. Results: : Twenty patients were enrolled and 16 completed the study. There were improvements in PHQ-9, CGI-S, SDS, and GAD-7 scores from baseline at Week 12, with a mean difference of -4.8, -1.3, -8.5, and -6.2, respectively. The CGI-I score improved from baseline with a mean score of 2.3 at Week 12. One third achieved response and 25% achieved remission based on PHQ-9 scores at Week 12. Similar results were obtained using CGI-S scores (38% for both). The incidences of adverse events (AEs) and treatment-related AEs were 55% (11/20) and 50% (10/20), respectively. There were no deaths or severe AEs. Two patients withdrew brexpiprazole during the study. Conclusion: : The observed effects and safety of adjunctive brexpiprazole in Asian adults with MDD in the real-world setting in Singapore were consistent with those from clinical trials. |
| References: | Arch Intern Med. 2006 May 22;166(10):1092-7. (PMID: 16717171) Curr Med Res Opin. 2018 Apr;34(4):633-642. (PMID: 29343128) J Clin Psychopharmacol. 2019 May/Jun;39(3):203-209. (PMID: 30946704) J Clin Psychiatry. 2015 Sep;76(9):1224-31. (PMID: 26301701) J Affect Disord. 2022 Dec 15;319:646-654. (PMID: 36167246) Expert Opin Pharmacother. 2019 Oct;20(15):1907-1916. (PMID: 31290344) J Clin Psychiatry. 2015 Sep;76(9):1232-40. (PMID: 26301771) CNS Spectr. 2014 Dec;19(6):528-34. (PMID: 24642260) Clin Psychopharmacol Neurosci. 2024 Feb 29;22(1):159-168. (PMID: 38247422) J Pharmacol Exp Ther. 2014 Sep;350(3):589-604. (PMID: 24947465) Cleve Clin J Med. 2008 Jan;75(1):57-66. (PMID: 18236731) Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:89-95. (PMID: 8923116) J Eval Clin Pract. 2008 Dec;14(6):979-83. (PMID: 18462279) Am J Psychiatry. 2006 Sep;163(9):1519-30; quiz 1665. (PMID: 16946176) Hum Psychopharmacol. 2013 Nov;28(6):544-51. (PMID: 24519690) J Clin Psychiatry. 2018 May 22;79(4):. (PMID: 29873953) Curr Med Res Opin. 2010 Oct;26(10):2475-84. (PMID: 20825269) Brain Behav. 2016 Jul 24;6(10):e00520. (PMID: 27781135) Curr Med Res Opin. 2018 Nov;34(11):1975-1984. (PMID: 29768955) Lancet Psychiatry. 2022 Feb;9(2):137-150. (PMID: 35026139) Nepal J Epidemiol. 2020 Sep 30;10(3):878-887. (PMID: 33042591) Asia Pac Psychiatry. 2013 Dec;5(4):249-58. (PMID: 24123813) Eur Respir J. 2008 Nov;32(5):1141-3. (PMID: 18978131) Patient Prefer Adherence. 2015 Mar 11;9:421-8. (PMID: 25792815) J Gen Intern Med. 2001 Sep;16(9):606-13. (PMID: 11556941) J Clin Psychiatry. 2009;70 Suppl 6:16-25. (PMID: 19922740) |
| فهرسة مساهمة: | Keywords: Adjunctive treatment; Antidepressants; Asian; Major depressive disorder; Real world |
| تواريخ الأحداث: | Date Created: 20240729 Latest Revision: 20240802 |
| رمز التحديث: | 20240802 |
| مُعرف محوري في PubMed: | PMC11289608 |
| DOI: | 10.9758/cpn.23.1143 |
| PMID: | 39069693 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1738-1088 |
|---|---|
| DOI: | 10.9758/cpn.23.1143 |